Oncología Traslacional
ONCTRAS
Copenhagen University Hospital
Copenhague, DinamarcaCopenhagen University Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (35)
2024
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future Oncology, Vol. 20, Núm. 13, pp. 799-809
-
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of Oncology
-
Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic
Archives of Gynecology and Obstetrics, Vol. 310, Núm. 1, pp. 577-586
-
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe
International Journal of Gynecological Cancer
2023
-
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
Cancers, Vol. 15, Núm. 13
-
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions
International Journal of Gynecological Cancer, Vol. 33, Núm. 11, pp. 1733-1742
-
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
European Journal of Cancer, Vol. 189
-
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Cancer, Vol. 129, Núm. 12, pp. 1846-1855
-
Safety and management of niraparib monotherapy in ovarian cancer clinical trials
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 971-981
2022
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384
-
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Annals of Oncology, Vol. 33, Núm. 3, pp. 276-287
-
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 174, pp. 221-231
-
Niraparib treatment for patients with BRCA-mutated ovarian cancer: Review of clinical data and therapeutic context
Future Oncology, Vol. 18, Núm. 23, pp. 2505-2536
-
Sex-specific regulation of IL-10 production in human adipose tissue in obesity
Frontiers in Endocrinology, Vol. 13
2021
-
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Radiotherapy and Oncology, Vol. 154, pp. 327-353
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39
-
ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors
Ultrasound in Obstetrics and Gynecology
-
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
The Lancet. Oncology, Vol. 22, Núm. 5, pp. 609-619